-
3D Medicines Files IPO Prospectus for Hong Kong Listing
•
China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the Hong Kong Stock Exchange (HKSE), though the issuance amount and price have yet to be disclosed. Company ProfileFounded in 2014, 3D Medicines has a product pipeline that includes envafolimab, a programmed-death ligand 1 (PD-L1) inhibitor…
-
I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors
•
I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been dosed in a global multi-center Phase I clinical study for its TJ-CD4B (ABL111), a bispecific antibody (BsAb) targeting Claudin 18.2 (CLDN18.2) and 4-1BB, in solid tumors including gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, and…
-
Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development
•
Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical giant Sanofi, securing exclusive worldwide rights to Sanofi’s siRNA platform of chemical modification and delivery moiety, as well as rights to four pre-clinical candidates targeting undisclosed indications. Deal HighlightsThe agreement significantly expands Rona’s pipeline in…
-
ApolloBio Corp. Initiates Pre-Clinical Study for ABC-5100 Nanobody Against COVID-19
•
ApolloBio Corp. (NEEQ:430187) announced the initiation of a pre-clinical study for its novel broad-spectrum anti-COVID-19 nanobody, ABC-5100. The drug is designed to prevent or provide early treatment for SARS-CoV-2 coronavirus infections. Pre-Clinical Study DetailsABC-5100 has demonstrated efficacy against various variants of concern (VOCs), including Omicron. The nanobody can be administered…
-
InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B
•
China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115 million shares on the Shanghai Stock Exchange’s Science and Technology Innovation Board (STAR). The shares were priced at RMB 18.12 (USD 2.68) each, raising a total of RMB 2.08 billion (USD 308 million) and valuing…
-
NMPA Releases 56th Batch of GQCE Reference Drugs, Including 14 Injectables
•
The National Medical Products Administration (NMPA) has released the 56th batch of reference drugs for generic quality consistency evaluation (GQCE) work, including 14 injectables among a total of 74 new specifications. Batch DetailsThe latest batch comprises 74 new drug specifications, with 14 being injectables. This marks the continued expansion of…
-
MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline
•
China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8 million) in a Series A+ financing round led by LYFE Capital. Existing investor Source Code Capital and a government-led fund also participated. Funding UseProceeds will support the expansion of MobiDrop’s single-cell product pipeline, research and…
-
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
•
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005 in breast cancer treatment has successfully met pre-set endpoints. The study demonstrated that LY01005 effectively controls serum estradiol to postmenenopausal levels, with clinical efficacy comparable to a control drug, achieving a non-inferiority standard. Study DetailsThe…
